Source: Annual Congress 2013 –COPD mechanisms
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ostrovskyy, I. Savelikhina, O. Varunkiv, M. Kulynych-Miskiv, G. Korzh (Ivano-Frankivsk, Ukraine). Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD. Eur Respir J 2013; 42: Suppl. 57, 2155

Member's Comments

No comment yet.

Related content which might interest you: Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD Source: International Congress 2014 – Markers Year: 2014 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 Bacterial infection in hospitalized patients of acute exacerbation of COPD and their relation to lung function: A prospective study Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients Year: 2016 Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model) Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Additive effect of targeted lung denervation plus drug in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Bronchodilator response of advanced lung function parameters depending on COPD severity Source: International Congress 2016 – Functional assessment of the airways Year: 2016 Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014